The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank
Open accessAbstract
Objective: Lp(a) (lipoprotein[a]) concentrations are associated with atherosclerotic cardiovascular disease (ASCVD), and new therapies that enable potent and specific reduction are in development. In the largest study conducted to date, we address 3 areas of uncertainty: (1) the magnitude and shape of ASCVD risk conferred across the distribution of lipoprotein(a) concentrations; (2) variation of risk across racial and clinical subgroups; (3) clinical importance of a high lipoprotein(a) threshold to guide therapy. Approach and Results: Relationship of lipoprotein(a) to incident ASCVD was studied in 460 506 middle-aged UK Biobank participants. Over a median follow-up of 11.2 years, incident ASCVD occurred in 22 401 (4.9%) participants. Median lipoprotein(a) concentration was 19.6 nmol/L (25th–75th percentile 7.6–74.8). The relationship between lipoprotein(a) and ASCVD appeared linear across the distribution, with a hazard ratio of 1.11 (95% CI, 1.10–1.12) per 50 nmol/L increment. Substantial differences in concentrations were noted according to race—median values for white, South Asian, black, and Chinese individuals were 19, 31, 75, and 16 nmol/L, respectively. However, risk per 50 nmol/L appeared similar—hazard ratios of 1.11, 1.10, and 1.07 for white, South Asian, and black individuals, respectively. A high lipoprotein(a) concentration defined as ≥150 nmol/L was present in 12.2% of those without and 20.3% of those with preexisting ASCVD and associated with hazard ratios of 1.50 (95% CI, 1.44–1.56) and 1.16 (95% CI, 1.05–1.27), respectively. Conclusions: Lipoprotein(a) concentrations predict incident ASCVD among middle-aged adults within primary and secondary prevention contexts, with a linear risk gradient across the distribution. Concentrations are variable across racial subgroups, but the associated risk appears similar.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, genetic studies found a causal link between elevated Lp(a) levels and a higher risk for CVD diseases,[184–189] and vice versa [190].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [189]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437741.48606.98 · Cited by 3,697
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., Natarajan, P., Lander, E. S., Lubitz, S. A., Ellinor, P. T., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0183-z · Cited by 2,953
Self-citationCollaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,383
Cited by
Sorted by citations
Items 401–500 of 573
Lipoprotein(a) levels and cardiovascular mortality risk in Chinese patients undergoing hemodialysis
Liang, Q., Zhang, G., Jiang, L., Li, B., & Song, K. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04459-5 · Cited by 1
Hyperlipoproteinemia(a) and its impact on prognosis in patients with acute coronary syndrome
Bliznyuk, S. А., Komarovа, A. G., Владиславович, Е. М., & Chashchin, M. G. (2025) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin20252002137 · Cited by 1
Sohn, W. Y., Tan, K. C. B., Shah, T., Du, Y., Wang, J., Zhang, S., Flach, S. D., & Ward, J. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.07.021 · Cited by 1
Lipoprotein(a) and risk of recurrent atrial fibrillation after pulsed field ablation
Zuin, M., Canovi, L., Vitali, F., Balla, C., Malagù, M., & Bertini, M. (2025) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001787 · Cited by 1
Asbaita, M., Albaree, M., Mokhtar, J., Baroodi, N., Badla, B. A., Abdalbari, K., Najjar, A. A., Avci, M., & El‐Tamimi, H. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133996 · Cited by 2
Iwanowski, M., Ruiz, S., Vime‐Jubany, J., Zuccarino, F., Zerpa, D. Á. P., Jimenez-Mayorga, L., Rodríguez, S., Rodriguez, N., Cabero, P., Ivern, C., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101416 · Cited by 1
Machine learning to predict elevated lipoprotein(a)
Aminorroaya, A., & Khera, R. (2026) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001024 · Cited by 1
Li, X., Wang, Z., Liang, J., Li, B., Meng, Q., & Gao, M. (2026) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001794 · Cited by 1
Thomas, P. E., Nielsen, S. F., Nordestgaard, B. G., & Kamstrup, P. R. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag106 · Cited by 1
Tognola, C., Bernasconi, D. P., Rebora, P., Intravaia, R. C. M., Mancusi, C., Visco, V., Cesaro, A., Golia, E., Fucile, I., Merlini, P., et al. (2026) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-026-00781-w · Cited by 1
Parsa, S., Shah, P., Furst, A., Dudum, R., Din, N., Maron, D. J., Heidenreich, P. A., Ward, J. H., Lozama, A., Sandhu, A. T., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.046519 · Cited by 1
Machine learning-driven prioritization of lipoprotein(a) testing: model development and validation
Stevens, C. A. T., Barkas, F., Brandts, J., Kwilasi, S., Dharmayat, K., Elshorbagy, A. K., Karungi, I., Mahani, A. S., Sharabiani, M. T. A., Vallejo‐Vaz, A. J., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag185 · Cited by 1
Almahmeed, W. A., Sabbour, H. M., Shantouf, R. S., Aljaberi, A. K., Tamimi, H. E., Lootah, F. B., Sayed, N. A., Ali, J. A., Akbar, M. A. J., Shehab, A., et al. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100569 · Cited by 1
Yang, K., Liu, S., Wang, C., Ni, S., Bi, L., Yang, Y., & Zhang, M. (2026) · Open Heart · doi:10.1136/openhrt-2025-003704 · Cited by 1
Translating Lipoprotein Genetics Into New Therapies
Hegele, R. A. (2026) · Circulation Research · doi:10.1161/circresaha.126.328828 · Cited by 1
Nadim, M. K., & Akgun, Y. (2026) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2026.104483 · Cited by 1
Evaluating elevated lipoprotein(a) clinical care impact in an academic health center
Roman, A., Sacco, S. J., & Tiu, J. G. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.06.023 · Cited by 1
Lipoprotein(a) and calcific aortic stenosis: from inherited risk marker to therapeutic target
Epelde, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1908850 · Cited by 1
Lipoprotein(a) in Japan: when ‘moderately elevated’ might already mean high risk
Kronenberg, F. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag607 · Cited by 1
Lipoprotein(a) management simplified: The National Lipid Association lipid simplified series
Koschinsky, M. L., & Ballantyne, C. M. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.013 · Cited by 1
Malick, W. A., Rosenson, R. S., Naidu, I., & Mechanick, J. I. (2025) · Springer eBooks · doi:10.1007/978-3-031-82888-1_5 · Cited by 1
KILDA: identifying KIV-2 repeats from kmers
Molitor, C., Labidi, T., Rimbert, A., Cariou, B., Filippo, M. D., & Bardel, C. (2025) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqaf070 · Cited by 1
Multiplexed Quantification of First-Trimester Serum Biomarkers in Healthy Pregnancy
Starodubtseva, N. L., Tokareva, A., Kononikhin, A. S., Brzhozovskiy, A. G., Bugrova, A. E., Kukaev, E., Poluektova, A., Евгеньевич, Ф. В., Николаев, Е. Н., & Sukhikh, G. T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167970 · Cited by 1
Serum Proteomics of Ribociclib‐Mediated Cardiovascular Toxicity: An Exploratory Case–Control Study
Fiste, O., Samiotaki, M. K., Manios, E. D., Trika, C. O., Liacos, C., Dimitrakakis, C., Dimopoulos, M. A., Gavriatopoulou, M., & Zagouri, F. (2025) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.70021 · Cited by 1
The Role of Lipoprotein (a) in the Development of Cerebral Atherosclerosis
Кukharchuk, K. M., Cherska, М. S., Kazykina, T., & Pidlepenska, V. (2025) · Wiadomości Lekarskie · doi:10.36740/wlek/210019 · Cited by 1
Lipoprotein(a) testing in an outpatient cardiology clinic: A quality improvement initiative
Gruen, J., & Bajaj, A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.01.018 · Cited by 1
Adamopoulou, E., Dimitriadis, K. S., Sakalidis, A., Kyriakoulis, K., KOULOURIOTIS, A., Pyrpyris, N., Aznaouridis, K. A., Orfanos, P., Λάγιου, Π., & Tsioufis, K. T. K. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.038 · Cited by 1
Lipoprotein(a), apolipoprotein B and other lipid biomarkers in Asian healthcare workers
Loh, W. J., Tun, M. H., Shak, B., Phua, S. K., Lim, G., Yap, C., Khoo, J., Puar, T. H. K., Heng, C. K., Foo, R., et al. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02912-7 · Cited by 1
Lp(a) Has Specific Effects on Coronary Artery Disease Independent of LDL-C
Lee, M. P., Koenigsberg, S. H., Anwar, M. Y., Raffield, L. M., Lin, Z., Ballou, A. F., Booth, J. N., Davy-Méndez, T., Kassahun, H., Kent, S. T., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102697 · Cited by 1
Alshibane, M. A. M., Ali, M. A. M., Ahmed, M. A., Elmubarak, S. M. S. E., Zain, N. Q. A. A. M., Elabdin, S. O. H. Z., & Mohammed, A. F. (2026) · Cureus · doi:10.7759/cureus.106009 · Cited by 1
Lipoprotein(a)-associated proteomic signature predicts cardiovascular disease in young adults
Goonewardena, S. N., Yao, S., Jurga, T., Zhang, L., Lloyd‐Jones, D. M., Damodaran, D., Thyagarajan, B., Jacobs, D. R., Shore, S., Brandt, E. J., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci204287 · Cited by 1
Chattopadhyay, S., Sangha, J., & Sathyapalan, T. (2026) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2026.103422 · Cited by 1
Correlation between serum and plasma lipoprotein(a) measurements: ARIC study
Bene-Alhasan, Y. O., Sun, C., Hamid, A., Nambi, V., Graff, M., Avery, C. L., Ballantyne, C. M., & Hoogeveen, R. C. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.05.226 · Cited by 1
Cesaro, A., Jamialahmadi, O., Pugliese, N., Flagiello, V., Barreby, E., Mancina, R. M., Calabrò, P., & Romeo, S. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101706 · Cited by 1
Yamashita, K., Wakita, M., Niizeki, N., Ito, S., Ito, Y., 佐藤, 麻., Miura, H., Yoshida, H., Masaki, T., Matsushita, K., et al. (2026) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.66345 · Cited by 1
Why and when should be lipoprotein(a) level measured?
Broncel, M., & Broncel, M. (2023) · Exploration of Cardiology · doi:10.37349/ec.2023.00015 · Cited by 1
Delgado‐Lista, J., Mostaza, J. M., Arrobas-Velilla, T., Blanco‐Vaca, F., Masana, L., Pedro‐Botet, J., Pérez‐Martínez, P., Civeira, F., Cuende, J. I., Gómez-Barrado, J. J., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.04.001 · Cited by 1
RetractedLipoprotein(a): Are we ready for large-scale clinical trials?
Zheng, S., Fang, G., Du, J., & Dong, J. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132236 · Cited by 1
Pavlyha, M., Hunter, M. D., Nowygrod, R., Patel, V. I., Morrissey, N. J., Bajakian, D. R., Li, Y., & Reyes‐Soffer, G. (2024) · JVS Vascular Science · doi:10.1016/j.jvssci.2024.100211 · Cited by 1
Wang, Q., McCormick, S. P. A., Leask, M., Watson, H., O'Sullivan, C., Krebs, J. D., Hall, R. M., Whitfield, P., Merry, T. L., Murphy, R., et al. (2024) · Bioscience Reports · doi:10.1042/bsr20240403 · Cited by 1
Frías, P. T., Martínez-Ballesta, A., Sánchez-Ramos, J. G., & Escobar, E. M. (2024) · Revista Española de Cardiología · doi:10.1016/j.recesp.2024.10.005 · Cited by 1
Perspectives on early health economic evaluations of RNA therapies targeted at lipoprotein(a)
Burvill, A., Watts, G. F., & Ademi, Z. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000904 · Cited by 1
Schirmer, B., & Schuler, J. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_11 · Cited by 1
Favereaux, S., Durlach, V., & Vercoustre, B. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00416-6 · Cited by 1
Xu, F., Tao, Y., Chen, L., Zhang, Y., Wang, B., Han, J., Deng, C., Liu, W., Fan, G., Liang, R., et al. (2025) · Thrombosis Journal · doi:10.1186/s12959-025-00741-9 · Cited by 1
Lipoprotein(a): A Cardiovascular Risk Factor Affecting Ethnic Minorities
Nelson, R. R., Watson, K. E., & Reyes‐Soffer, G. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-81034-4_3 · Cited by 1
Epidemiología y carga de morbilidad y mortalidad en dislipidemias y aterosclerosis
Borrayo–Sánchez, G. (2021) · Cardiovascular and Metabolic Science · doi:10.35366/100785 · Cited by 1
Benson, M. D. (2022) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2022.06.008 · Cited by 1
Goonewardena, S. N., Jurga, T., Lloyd‐Jones, D. M., Damodaran, D., Thyagarajan, B., Jacobs, D. R., Shore, S., Brandt, E. J., Clish, C. B., Tanrıverdi, K., et al. (2024) · medRxiv · doi:10.1101/2024.05.12.24307240 · Cited by 1
Elevated Lipoprotein(a) With Zero Coronary Artery Calcium: A Silent Threat or a Clinical Paradox?
Lozano, P. F. R., & Hosadurg, N. (2024) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.124.017136 · Cited by 1
Lipoprotein(a) is Associated with Increased Low-Density Plaque VolumePreprint
Fisher, R., Nurmohamed, N. S., Fisher, E. A. A., Aquino, M. B., Earls, J. P., Min, J. K., Gurevitz, C., Malick, W. A., Peters, M. R., Goonewardena, S. N., et al. (2024) · medRxiv · doi:10.1101/2024.07.18.24310539 · Cited by 1
Santangelo, G., Antonini‐Canterin, F., & Faggiano, P. M. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm26537 · Cited by 1
Lipoprotein(a) and High-Risk Coronary Plaque
Wee, S.-B., Ahn, J., Kang, D., Park, S., & Park, D. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.04.029 · Cited by 1
Lipoprotein(a) After HORIZON: Causal Culprit, Risk Marker, or Unfulfilled Therapeutic Promise?
Borovac, J. A., & Belančić, A. (2026) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484261492865 · Cited by 1
High Prevalence of Lipid-Related Residual Risk in ACS Patients
Ward, N. C., Pang, J., Chakraborty, A., Schultz, C. J., Chan, D. C., & Watts, G. F. (2021) · Heart Lung and Circulation · doi:10.1016/j.hlc.2021.10.006
Patel, A. P., & Khera, A. V. (2022) · Circulation · doi:10.1161/circulationaha.121.058059
Self-citationEl arte de la interpretación (Sobre las dislipidemias)
Enciso‐Muñoz, J. M. (2021) · Cardiovascular and Metabolic Science · doi:10.35366/100792
Kardiovaskuläre Prävention in Peri- und Postmenopause – Herz und Kreislauf gesund erhalten
Windler, E. E. T., & Zyriax, B. (2022) · Gynäkologische Endokrinologie · doi:10.1007/s10304-022-00458-2
Approche de la stratification du risque de maladies cardiovasculaires athéroscléreuses
Esau, D., & Abramson, B. L. (2022) · Canadian Family Physician · doi:10.46747/cfp.6809e256
Xu, Z. Y., Zhang, L. L., Wang, S. H., & Wang, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-2064069/v1
Olpasiran leads to dramatic reductions in Lp(a) concentrations
van den Heuvel, R. (2023) · doi:10.55788/ce9dfa18
Romandini, A., Baldassarre, D., Genovese, S., Capri, S., Pompilio, G., Scatigna, M., & Werba, J. P. (2023) · Pharmaceuticals · doi:10.3390/ph16020176
Schirmer, B., & Schuler, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-66303-5_11
The Role of Lp(a) in Atherosclerosis: An Overview
Matveyenko, A., Pavlyha, M., & Reyes‐Soffer, G. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_9
Lipoprotein(a) in Cardiovascular Disease: Evidence from Large Epidemiological Studies
Thomas, P. E., Vedel‐Krogh, S., & Nordestgaard, B. G. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_15
Elevated Lp(a): Why Should I Test For It, If I Cannot Treat It? A Patient’s Perspective
Tremulis, S. R. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_24
Lipoprotein(a) in Cardiovascular Risk Assessment
Boffa, M. B., Koschinsky, M. L., & Marcovina, S. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00005-4
Sumarni, S., Hartati, H., Harnany, A. S., Sarbini, D., Fadlilah, S., & Nugroho, A. (2023) · Malaysian Journal of Medicine and Health Sciences · doi:10.47836/mjmhs.19.6.16
The influence of lipoproteina(a) on cardio-vascular diseases
Maj-Dziedzic, M., Brzozowska, A., Sikora, M., Zarzycka, M., Plewniok, I., Dubiel, J., Maj, A., Śmietana, G., Warno, M., & Kozik, W. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.54.013
Schirmer, B., & Schuler, J. (2023) · Springer eBooks · doi:10.1007/978-3-662-68371-2_11
Espoirs et place prochaine potentielle des inhibiteurs de la Lp(a)
Guédon, A. F., Ghrenassia, E., Cohen, A. A., & Boccara, F. (2024) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.01.003
Schwartz, G. G. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.356
Skiba, I. B., Polushin, A. Y., Сергеевна, С. Е., Sokolov, A. S., Polyakova, E. A., Yanishevskiy, S. N., & Voznyuk, I. A. (2024) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2024-3-136-143
Personalised cardiovascular and lipid screening using machine learning approach
Chan, K., & Sobirov, I. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132725
Moiseeva, A. M., Ivanova, O. N., Emelyanchik, V. S., Emelyanchik, E. Y., Валерьевна, М. О., Nikulina, S. Y., & Protopopov, A. V. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-5927
Highlighting the Need for Comprehensive Cardiovascular Risk Assessment: Case Report
Mewborn, E., & Swanson, A. P. (2024) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2024.105282
Frías, P. T., Martínez-Ballesta, A., Sánchez-Ramos, J. G., & Escobar, E. M. (2024) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2024.10.013
Lipoprotein (a) Screening, and What's Next?
Pasławska, A., Radom, A., & Tomasik, P. (2024) · Journal of Cardiovascular Emergencies · doi:10.2478/jce-2024-0022
Maladkar, Y. T., & Kothiwale, V. A. (2024) · Journal of the Scientific Society · doi:10.4103/jss.jss_183_24
Esau, D., Nord, P., & Abramson, B. L. (2025) · Cardiology · doi:10.1159/000543403
The prognostic role of lipoprotein(a) in cardiovascular disease
Rhee, E. (2025) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2025.7.e3
Leveraging drug-target Mendelian randomization for tailored lipoprotein-lipid lowering
Gagnon, É., & Arsenault, B. J. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000977
Velilla, T. A., Fernández‐Prendes, C., Amigó, N., Calmarza, P., Anguila, S. C., Estébanez, B. C., Castro, M. J. C., Ceacero-Marín, D., Martínez, I. G., Palencia, M. M., et al. (2025) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2024-0090
Telis, N., Dai, H., Waring, A. A., Kann, D., Wyman, D., White, S. J., Khuder, B., Tanudjaja, F., Bolze, A., Levy, M. E., et al. (2025) · Genetics in Medicine Open · doi:10.1016/j.gimo.2025.102258
Lipoprotein(a) and Atherosclerosis
Wong, N. D., Bhatia, H. S., & Nasir, K. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.504
Eidensohn, Y., & O’Rourke, P. (2025) · Cureus · doi:10.7759/cureus.83859
The role of Lp(a) in cardiovascular diseases and treatment options
May, H. A., & Shurmur, S. W. (2022) · The Southwest Respiratory and Critical Care Chronicles · doi:10.12746/swrccc.v10i45.1079
Li, F., & Hukportie, D. N. (2025) · medRxiv · doi:10.1101/2025.05.22.25328169
Association between elevated Lp(a) and CAV in heart transplant recipientsPreprint
Cao, L., Huang, S., Amancherla, K. V., ZALAWADIYA, S. K., Siddiqi, H. K., Schlendorf, K. H., Lindenfeld, J. M., & Song, W. (2025) · medRxiv · doi:10.1101/2025.05.26.25328315
Lipoprotein(a) and coronary artery disease: The need for universal screening – A case-based review
Ngo, N. Y. N., Villavaso, C. D., Orakwue, C. J., Rowalt, W. Z., Roberts, M., & Ferdinand, K. C. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100560
Phenomapping of subgroups in high-Lp(a) patients: a data-driven cluster analysis in RED-CARPET study
Zhang, S., Lin, X., Zhan, R., Zhou, H., Lai, Y., Huang, M., Li, B., Liao, X., & Zhuang, X. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02669-6
Preechasuk, L., Kongmalai, T., Lapinee, V., Pratumvinit, B., & Thongtang, N. (2025) · Vascular Health and Risk Management · doi:10.2147/vhrm.s544693
Suta, S., Pinsawas, B., Surawit, A., Ophakas, S., Wang, Y., Du, Y. Y., Shen, X., Pasookhush, P., Mongkolsucharitkul, P., Soonkum, T., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7577991/v1
Casolo, G., & Meglio, J. D. (2025) · Cardiologia Ambulatoriale · doi:10.17473/1971-6818-2025-2-6
Zhu, X., Yan, L., Tang, L., Wang, J., Guo, Y., & Yang, P. (2025) · Europe PMC (PubMed Central) · doi:10.11817/j.issn.1672-7347.2025.240597
Truong, T., Anh, T. H., Hoang, S. V., Nguyen, N. Q., Hoa, T., Nguyen, D. C., Nguyen, H. D., Dang, H. N. N., Luong, T. V., Do, D. L., et al. (2025) · Health Science Reports · doi:10.1002/hsr2.71436
Emelyanchik, V. S., Moiseeva, A. M., Дмитренко, Д. В., Emelyanchik, E. Y., Евгеньевна, Т. Е., Vasilieva, A. A., Kachanova, T. V., Statnikova, N. M., Васильевна, Е. О., Nikulina, S. Y., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6445
Patient Characteristics Across Lipoprotein(a) Levels: Insights From a Retrospective Study
Howell, C. M., Nyhave, L. H., Raungaard, B., Handberg, A., Nielsen, C. G., Bork, C. S., & Venø, S. K. (2025) · Lipids · doi:10.1002/lipd.70025
Krintus, M., Dwojaczny, B., Wolska, A., Siódmiak, J., Szternel, Ł., Bergmann, K., Stefańska, A., & Panteghini, M. (2025) · Biochemia Medica · doi:10.11613/bm.2026.010702
Metadata
- Authors
- Patel, A. P., Wang, M., Pirruccello, J. P., Ellinor, P. T., Ng, K., Kathiresan, S., & Khera, A. V.
- Affiliations
- Broad Institute (US)
- IBM Research - Cambridge (United States) (US)
- Corresponding author
- Khera, Amit V.
- ORCID
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2021-01
- Volume
- 41
- Issue
- 1
- Pages
- 465-474
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- PMC
- PMC7769893
- OpenAlex
- W3097307979
- Cited by
- 567
- References
- 50
- Citations by year
- 2026: 135 · 2025: 147 · 2024: 110 · 2023: 89 · 2022: 60 · 2021: 25
- FWCI
- 39.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion, other-oa)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- American Heart Association (R01 HL128914, 18SFRN34110082)
- Massachusetts General Hospital
- Broad Institute
- Fondation Leducq (K24HL105780, 18SFRN34110082, 1RO1HL092577, T32HL007208, 14CVD01, R01HL128914)
- Medical Research Council (MC_PC_17228)
- National Heart, Lung, and Blood Institute (1RO1HL092577, R01HL128914, K24HL105780, R01HL092577, T32HL007208)
- National Human Genome Research Institute (K08HG010155, 18SFRN34110082)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- lipoprotein(a), atherosclerotic cardiovascular disease, incident cardiovascular events, racial differences, risk gradient, primary prevention, secondary prevention, middle-aged adults, UK Biobank
- MeSH terms
- Race Factors, Heart Disease Risk Factors, Adult, Aged, Female, United Kingdom, Humans, Male, Middle Aged, Primary Prevention, Prognosis, Time Factors, Biomarkers, Incidence, Lipoprotein(a), Biological Specimen Banks, Risk Assessment, Atherosclerosis, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
